Recently, we demonstrated that MET-amplified gastric cancer patients without co-amplification of other RTKs can benefit from MET inhibitors compared to standard second-line chemotherapy, based on NGS results from tissue specimens [35]. The gene discussed is MET; the disease is gastric cancer.